Nanotechnology-enhanced immunotherapy for metastatic cancer

A vast majority of cancer deaths occur as a result of metastasis. Unfortunately, effective treatments for metastases are currently lacking due to the difficulty of selectively targeting these small, delocalized tumors distributed across a variety of organs. However, nanotechnology holds tremendous p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peisen Zhang, Junli Meng, Yingying Li, Chen Yang, Yi Hou, Wen Tang, Kevin J. McHugh, Lihong Jing
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	metastatic cancer nanomaterials immunotherapy tumor microenvironments immunomodulators Science (General) Q1-390
Acceso en línea:	https://doaj.org/article/087464a30b9148ea87c60af7c3e1b180
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:087464a30b9148ea87c60af7c3e1b180
record_format	dspace
spelling	oai:doaj.org-article:087464a30b9148ea87c60af7c3e1b1802021-11-28T04:39:15ZNanotechnology-enhanced immunotherapy for metastatic cancer2666-675810.1016/j.xinn.2021.100174https://doaj.org/article/087464a30b9148ea87c60af7c3e1b1802021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666675821000990https://doaj.org/toc/2666-6758A vast majority of cancer deaths occur as a result of metastasis. Unfortunately, effective treatments for metastases are currently lacking due to the difficulty of selectively targeting these small, delocalized tumors distributed across a variety of organs. However, nanotechnology holds tremendous promise for improving immunotherapeutic outcomes in patients with metastatic cancer. In contrast to conventional cancer immunotherapies, rationally designed nanomaterials can trigger specific tumoricidal effects, thereby improving immune cell access to major sites of metastasis such as bone, lungs, and lymph nodes, optimizing antigen presentation, and inducing a persistent immune response. This paper reviews the cutting-edge trends in nano-immunoengineering for metastatic cancers with an emphasis on different nano-immunotherapeutic strategies. Specifically, it discusses directly reversing the immunological status of the primary tumor, harnessing the potential of peripheral immune cells, preventing the formation of a pre-metastatic niche, and inhibiting the tumor recurrence through postoperative immunotherapy. Finally, we describe the challenges facing the integration of nanoscale immunomodulators and provide a forward-looking perspective on the innovative nanotechnology-based tools that may ultimately prove effective at eradicating metastatic diseases. Public summary: • The state of the art for nanotechnology-enabled cancer immunotherapy and the emerging concepts in nano-based immunomodulation are summarized • The cutting-edge trends in nano-immunoengineering for metastatic cancers with an emphasis on different nano-immunotherapeutic strategies are highlighted • Benefits, challenges, and opportunities of nanoscale immunomodulators and a forward-looking perspective on the innovative nanotechnology-based tools that may ultimately prove effective at eradicating metastatic diseases are presentedPeisen ZhangJunli MengYingying LiChen YangYi HouWen TangKevin J. McHughLihong JingElsevierarticlemetastatic cancernanomaterialsimmunotherapytumor microenvironmentsimmunomodulatorsScience (General)Q1-390ENThe Innovation, Vol 2, Iss 4, Pp 100174- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	metastatic cancer nanomaterials immunotherapy tumor microenvironments immunomodulators Science (General) Q1-390
spellingShingle	metastatic cancer nanomaterials immunotherapy tumor microenvironments immunomodulators Science (General) Q1-390 Peisen Zhang Junli Meng Yingying Li Chen Yang Yi Hou Wen Tang Kevin J. McHugh Lihong Jing Nanotechnology-enhanced immunotherapy for metastatic cancer
description	A vast majority of cancer deaths occur as a result of metastasis. Unfortunately, effective treatments for metastases are currently lacking due to the difficulty of selectively targeting these small, delocalized tumors distributed across a variety of organs. However, nanotechnology holds tremendous promise for improving immunotherapeutic outcomes in patients with metastatic cancer. In contrast to conventional cancer immunotherapies, rationally designed nanomaterials can trigger specific tumoricidal effects, thereby improving immune cell access to major sites of metastasis such as bone, lungs, and lymph nodes, optimizing antigen presentation, and inducing a persistent immune response. This paper reviews the cutting-edge trends in nano-immunoengineering for metastatic cancers with an emphasis on different nano-immunotherapeutic strategies. Specifically, it discusses directly reversing the immunological status of the primary tumor, harnessing the potential of peripheral immune cells, preventing the formation of a pre-metastatic niche, and inhibiting the tumor recurrence through postoperative immunotherapy. Finally, we describe the challenges facing the integration of nanoscale immunomodulators and provide a forward-looking perspective on the innovative nanotechnology-based tools that may ultimately prove effective at eradicating metastatic diseases. Public summary: • The state of the art for nanotechnology-enabled cancer immunotherapy and the emerging concepts in nano-based immunomodulation are summarized • The cutting-edge trends in nano-immunoengineering for metastatic cancers with an emphasis on different nano-immunotherapeutic strategies are highlighted • Benefits, challenges, and opportunities of nanoscale immunomodulators and a forward-looking perspective on the innovative nanotechnology-based tools that may ultimately prove effective at eradicating metastatic diseases are presented
format	article
author	Peisen Zhang Junli Meng Yingying Li Chen Yang Yi Hou Wen Tang Kevin J. McHugh Lihong Jing
author_facet	Peisen Zhang Junli Meng Yingying Li Chen Yang Yi Hou Wen Tang Kevin J. McHugh Lihong Jing
author_sort	Peisen Zhang
title	Nanotechnology-enhanced immunotherapy for metastatic cancer
title_short	Nanotechnology-enhanced immunotherapy for metastatic cancer
title_full	Nanotechnology-enhanced immunotherapy for metastatic cancer
title_fullStr	Nanotechnology-enhanced immunotherapy for metastatic cancer
title_full_unstemmed	Nanotechnology-enhanced immunotherapy for metastatic cancer
title_sort	nanotechnology-enhanced immunotherapy for metastatic cancer
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/087464a30b9148ea87c60af7c3e1b180
work_keys_str_mv	AT peisenzhang nanotechnologyenhancedimmunotherapyformetastaticcancer AT junlimeng nanotechnologyenhancedimmunotherapyformetastaticcancer AT yingyingli nanotechnologyenhancedimmunotherapyformetastaticcancer AT chenyang nanotechnologyenhancedimmunotherapyformetastaticcancer AT yihou nanotechnologyenhancedimmunotherapyformetastaticcancer AT wentang nanotechnologyenhancedimmunotherapyformetastaticcancer AT kevinjmchugh nanotechnologyenhancedimmunotherapyformetastaticcancer AT lihongjing nanotechnologyenhancedimmunotherapyformetastaticcancer
_version_	1718408238510112768

Nanotechnology-enhanced immunotherapy for metastatic cancer

Ejemplares similares